[go: up one dir, main page]

OA11494A - Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline. - Google Patents

Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline. Download PDF

Info

Publication number
OA11494A
OA11494A OA1200000268A OA1200000268A OA11494A OA 11494 A OA11494 A OA 11494A OA 1200000268 A OA1200000268 A OA 1200000268A OA 1200000268 A OA1200000268 A OA 1200000268A OA 11494 A OA11494 A OA 11494A
Authority
OA
OAPI
Prior art keywords
trifluoromethyl
ethyl
dihydro
quinoline
carboxylic acid
Prior art date
Application number
OA1200000268A
Other languages
English (en)
French (fr)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11494A publication Critical patent/OA11494A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200000268A 1999-11-30 2000-09-29 Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline. OA11494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
OA11494A true OA11494A (en) 2004-05-07

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000268A OA11494A (en) 1999-11-30 2000-09-29 Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.

Country Status (45)

Country Link
US (1) US6313142B1 (ru)
EP (1) EP1125929B1 (ru)
JP (1) JP3579345B2 (ru)
KR (1) KR100408177B1 (ru)
CN (1) CN1173953C (ru)
AP (1) AP2000002011A0 (ru)
AR (1) AR029775A1 (ru)
AT (1) ATE315028T1 (ru)
AU (1) AU784694B2 (ru)
BG (1) BG105009A (ru)
BR (1) BR0005636A (ru)
CA (1) CA2327029C (ru)
CO (1) CO5261552A1 (ru)
CY (1) CY1104989T1 (ru)
CZ (1) CZ20004407A3 (ru)
DE (1) DE60025317T2 (ru)
DK (1) DK1125929T3 (ru)
DZ (1) DZ3079A1 (ru)
EA (1) EA003668B1 (ru)
EE (1) EE200000659A (ru)
ES (1) ES2254109T3 (ru)
GE (1) GEP20022798B (ru)
GT (1) GT200000190A (ru)
HK (1) HK1038007A1 (ru)
HN (1) HN2000000203A (ru)
HR (1) HRP20000804A2 (ru)
HU (1) HUP0004747A3 (ru)
ID (1) ID28489A (ru)
IL (1) IL139849A (ru)
IS (1) IS5715A (ru)
MA (1) MA25223A1 (ru)
NO (1) NO20006039L (ru)
NZ (1) NZ508509A (ru)
OA (1) OA11494A (ru)
PA (1) PA8503801A1 (ru)
PE (1) PE20010913A1 (ru)
PL (1) PL344208A1 (ru)
SG (1) SG102603A1 (ru)
SK (1) SK17792000A3 (ru)
TN (1) TNSN00230A1 (ru)
TW (1) TW591016B (ru)
UA (1) UA65615C2 (ru)
UY (1) UY26451A1 (ru)
YU (1) YU71500A (ru)
ZA (1) ZA200006947B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
US7279297B2 (en) * 2002-04-11 2007-10-09 Roar Holding Llc Ex vivo method for determination of CETP activity and efficacy of heart disease treatment
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
WO2004082593A2 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Pharmaceutical compositions of cetp inhibitors
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EA200600737A1 (ru) * 2003-10-08 2006-10-27 Эли Лилли Энд Компани Соединения и способы для лечения дислипидемии
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MXPA06014716A (es) * 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
IL317973A (en) 2022-07-05 2025-02-01 Newamsterdam Pharma B V Salts of ovicetrapib and processes for their production and intermediates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (ru) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
JP3579345B2 (ja) 2004-10-20
ES2254109T3 (es) 2006-06-16
EE200000659A (et) 2001-08-15
EP1125929B1 (en) 2006-01-04
NZ508509A (en) 2001-06-29
SK17792000A3 (sk) 2002-10-08
DK1125929T3 (da) 2006-04-03
BR0005636A (pt) 2001-07-17
IS5715A (is) 2001-05-31
PE20010913A1 (es) 2001-09-10
EA200001129A2 (ru) 2001-06-25
KR100408177B1 (ko) 2003-12-01
CZ20004407A3 (cs) 2002-06-12
HRP20000804A2 (en) 2001-06-30
HN2000000203A (es) 2001-06-13
NO20006039D0 (no) 2000-11-29
MA25223A1 (fr) 2001-07-02
AU784694B2 (en) 2006-06-01
US6313142B1 (en) 2001-11-06
NO20006039L (no) 2001-05-31
TNSN00230A1 (fr) 2005-11-10
HUP0004747A2 (hu) 2001-10-28
CY1104989T1 (el) 2010-03-03
CN1173953C (zh) 2004-11-03
PA8503801A1 (es) 2002-07-30
DZ3079A1 (fr) 2004-10-24
JP2001163859A (ja) 2001-06-19
DE60025317D1 (de) 2006-03-30
KR20010052012A (ko) 2001-06-25
CA2327029A1 (en) 2001-05-30
BG105009A (en) 2001-11-30
CO5261552A1 (es) 2003-03-31
CN1302800A (zh) 2001-07-11
AR029775A1 (es) 2003-07-16
IL139849A (en) 2006-10-31
TW591016B (en) 2004-06-11
AU7178900A (en) 2001-05-31
DE60025317T2 (de) 2006-08-03
EA200001129A3 (ru) 2001-10-22
SG102603A1 (en) 2004-03-26
EA003668B1 (ru) 2003-08-28
YU71500A (sh) 2003-02-28
UY26451A1 (es) 2001-06-29
PL344208A1 (en) 2001-06-04
ATE315028T1 (de) 2006-02-15
CA2327029C (en) 2005-08-09
HUP0004747A3 (en) 2002-12-28
ZA200006947B (en) 2002-05-27
AP2000002011A0 (en) 2000-12-31
GEP20022798B (en) 2002-09-25
UA65615C2 (ru) 2004-04-15
HU0004747D0 (ru) 2001-02-28
HK1038007A1 (en) 2002-03-01
EP1125929A1 (en) 2001-08-22
GT200000190A (es) 2002-04-27
ID28489A (id) 2001-05-31
IL139849A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
OA11494A (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.
OA12099A (en) 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor.
TWI685486B (zh) 製備ｐｄｅ４抑制劑之方法
WO2001070731A1 (en) Decahydro-isoquinolines
JP5078993B2 (ja) １−（３，４−ジクロロベンジル）−５−オクチルビグアナイドまたはその塩の製造方法
TWI491607B (zh) ４，４’-（１-甲基-１，２-乙二基）-雙-（２，６-哌二酮）之新製法
JPS6123790B2 (ru)
US20080058523A1 (en) Processes for synthesizing piperazine-piperidine compounds
US6063784A (en) Heteroaryloxyethylamines, method of preparation, application as medicine and pharmaceutical compositions containing them
MXPA00011855A (en) Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester
JPH0525162A (ja) キノロン誘導体およびその製造法
JP3225107B2 (ja) 光学活性２−プロパノール誘導体の製造法
JP2002088081A (ja) 新規ナフチリジン誘導体またはその薬理学的に許容される塩